LivaNova PLC, a company formed from the merger of Sorin and Cyberonics, landed FDA approval for its CROWN PRT stented prosthetic aortic valve. The leaflets of the valve have been put through Phospholipid Reduction Treatment (PRT), a technique that promotes a considerably longer working life for the implant by reducing the deposition of calcium on the surface. The bovine pericardium leaflets open wide because they’re placed outside the stent, allowing blood to move through easily.
The firm claims the design of the CROWN PRT makes it easy to implant and results in a tight fit, leading to “optimal” hemodynamics around the valve.
The company only last month received approval for its Perceval sutureless valve.
Product page: CROWN PRT…
Source: LivaNova…